Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.40 |
| ▸ | NFKBIA | P25963 | 3/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5843572 | 0.75 | COMT (0.46) | CCR1GLO1SLC40A1MEN1KMT2A | |
| SCHEMBL7186476 | 0.74 | NPSR1 (0.52) | CCR1RAB9ACCR5MEN1KMT2A | |
| SCHEMBL1974625 | 0.73 | CCR1 (0.48) | CCR1RAB9ACCR5AGTR1MEN1 | |
| SCHEMBL13713001 | 0.70 | CYP1A2 (0.55) | RAB9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL29923496 | 0.69 | RAB9A (0.43) | CCR1RAB9ACCR5MEN1KMT2A | |
| SCHEMBL3332400 | 0.69 | CCR1 (0.43) | CCR1RAB9ACCR5NFKBIATDP1 | |
| SCHEMBL9209719 | 0.68 | CYP1A2 (0.53) | PTGS2 | |
| SCHEMBL27512952 | 0.68 | CCR1 (0.42) | CCR1RAB9ACCR5MEN1KMT2A | |
| SCHEMBL29239824 | 0.67 | PTGS2 (0.42) | ALDH1A1PTGS2ATM | |
| SCHEMBL30679979 | 0.67 | TBK1 (0.41) | RAB9ASLC40A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100508978-C | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK & CO INC MERCK FROSST CA (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | disclosed |
| US-7153968-B2 | 8-(biaryl)quinoline PDE4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2006-12-26 | — | — | US | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | disclosed |
| CN-1221534-C | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2005-10-05 | — | — | CN | disclosed |
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | disclosed |
| EP-1487797-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-12-22 | — | — | EP | disclosed |
| CN-1551769-A | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | — | 2004-12-01 | — | — | CN | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
| CN-1434801-A | Substited 8-anylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2003-08-06 | — | — | CN | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | CCR1 115/4885RAB9A 536/4885CCR5 333/4885 |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | CCR1 3117/4885RAB9A 1060/4885CCR5 1988/4885 |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | IL4, PDE4A, PDE4C | CCR1 230/4885RAB9A 1465/4885CCR5 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.